Boston Scientific (NYSE: BSX) furnishes Q4 and full-year 2025 results release

Rhea-AI Filing Summary

Boston Scientific Corporation furnished a Form 8-K to announce it issued a press release with financial results for the fourth quarter and full year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and is furnished rather than filed for liability purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000885725false00008857252026-02-042026-02-040000885725us-gaap:CommonStockMember2026-02-042026-02-040000885725bsx:SeniorNotedue2027Member2026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934 

_____________________________________________________________________

Date of Report (Date of earliest event reported): February 4, 2026

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234

        (Address of Principal Executive Offices)                          (Zip Code)

508 683-4000

(Registrant's telephone number, including area code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 4, 2026, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits

Exhibit No.        Description

99.1            Press Release issued by Boston Scientific Corporation dated February 4, 2026

104            Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL

            document

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:			February 4, 2026			BOSTON SCIENTIFIC CORPORATION
						By:			/s/ Susan Thompson
									Susan Thompson
									Vice President, Chief Corporate Counsel and Assistant Secretary

FAQ

What did Boston Scientific (BSX) disclose in this 8-K filing?

Boston Scientific disclosed that it issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. The release is attached as Exhibit 99.1 and is treated as furnished, not filed, under the Securities Exchange Act of 1934.

When did Boston Scientific (BSX) release its Q4 and full-year 2025 results?

Boston Scientific released its fourth quarter and full-year 2025 financial results on February 4, 2026. That date is both the earliest event reported and the date of the attached press release identified as Exhibit 99.1 in the Form 8-K filing.

Where can investors find the detailed financial results mentioned in Boston Scientific’s 8-K?

Detailed financial results are contained in the press release furnished as Exhibit 99.1 to the Form 8-K. The filing states that Boston Scientific issued this press release on February 4, 2026, covering results for the quarter and year ended December 31, 2025.

How is the Exhibit 99.1 press release treated under U.S. securities laws?

The Exhibit 99.1 press release is explicitly described as furnished, not filed, under Section 18 of the Securities Exchange Act of 1934. This means it is not subject to Section 18 liabilities and is not incorporated by reference into other Securities Act or Exchange Act filings.

What SEC item does Boston Scientific use to report these financial results?

Boston Scientific uses Item 2.02, Results of Operations and Financial Condition, on Form 8-K to report issuing the press release. This item covers the company’s communication of financial results for the fourth quarter and full year ended December 31, 2025.

Which securities of Boston Scientific are listed in this 8-K filing?

The filing lists Boston Scientific’s common stock with a par value of $0.01 per share, trading under symbol BSX on the New York Stock Exchange, and its 0.625% Senior Notes due 2027, trading under symbol BSX27 on the New York Stock Exchange.